References
- Ayd F. Fatal hyperpyrexia during treatment with chlorpromazine therapy. Journal of Clinical Psychiatry 1956; 27: 189–192
- Delay J, Deniker P. Drug induced extra pyramidal syndrome. Handbook of clinical neurology. Vol. 6. New York: Elsevier, D Vinken, G Bruyen, 1968; 248–266
- Pope H, Keck P, McElroy S. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. American Journal of Psychiatry 1986; 143: 1227–1233
- Levenson J. Neuroleptic malignant syndrome. American Journal of Psychiatry 1985; 142: 1137–1145
- Reilly J, Crowe S, Lloyd J. Neuroleptic toxicity syndromes: a clinical spectrum. Australian and New Zealand Journal of Psychiatry 1991; 25: 499–505
- Risperdal product information. Janssen-Cilag,. 1993
- Lieberman J. Understanding the mechanism of action of atypical antipsychotic drugs. British Journal of Psychiatry 1993; 163: 7–18
- Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. American Journal of Psychiatry 1989; 146: 717–725
- Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatrica Scandinavica 1986; 73: 337–347